While Arena Pharmaceuticals (ARNA) and VIVUS (VVUS), makers of the obesity drugs Belviq and Qsymia, respectively, both garner a lot of attention on Fool.com, they also have attracted the attention of the short sellers. In this video, Motley Fool health-care analyst David Williamson talks about the "buy the run-up, short the launch" trend, and whether the short-sellers are right not to believe in these stocks.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Are the Shorts Right About Obesity Drugs?
NASDAQ: ARNA
Arena Pharmaceuticals

The two obesity-drug makers have caught the attention of short sellers. Are they right?
David Williamson owns shares of Amarin. Follow him on Twitter, @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.